![]() ![]() Initial clinical and laboratory characteristics when classified according to whether patients had bone age (BA) delay of more or less than 2 years. Finally, there was no significant difference in IGF-1 SDS between the groups at 6 and 12 months ( and, respectively). There also was no significant difference in height SDS at 6 and 12 months between the two groups ( and, respectively) (Figure 1). No significant change in BA/CA was observed in the groups with and without GH ( and, respectively). However, in the group with GHD, the height SDS increased significantly from baseline after 6 and 12 months of treatment (−2.42 ± 0.33 vs −1.87 ± 0.83 at 6 months and −1.73 ± 0.60 at 12 months ). In the group without GHD, there were no significant changes in height SDS at 6 and 12 months (−2.63 ± 0.52 vs −2.30 ± 0.74 at 6 months and −2.02 ± 0.99 at 12 months ). Initial clinical and laboratory characteristics when patients were classified according to the presence of growth hormone deficiency (GHD).Ĭhanges in height SDS, BA/CA, and IGF-1 SDS after 6 and 12 months of GH treatment were analyzed to identify whether there were any significant differences in GH treatment effects in patients with and without GHD. Among the 27 included SGA patients, 14 (51.9%) were diagnosed with GHD after GH stimulation testing. The mean ± SD age at the start of GH treatment was 7.2 ± 1.9 years, height SDS was −2.53 ± 0.44, and the body mass index (BMI) z-score was −0.51 ± 0.92. The mean gestational age was 37.7 ± 2.71 weeks, and the mean body weight at birth was 2239.25 ± 447.0 g. A total of 27 children were investigated in this study, of whom 10 were male (37%) and 17 were female (63%). Patient characteristics are given in Table 1. A value < 0.05 was considered to be statistically significant. Comparisons between the two groups were made using paired t tests, and repeated measures analysis of variance (ANOVA Greenhous-G) was used to analyze changes for 1 year after GH treatment. Statistical analyses were conducted using SPSS. For BA analysis, Greulich and Pyle atlas was used by two endocrinologists, and their readings were averaged. GH stimulation tests were performed in all patients: levodopa- and insulin-induced stimulation testing was conducted, and a human GH level <7 was defined as GHD. The patients were also classified into two groups based on whether they had GHD data between the two groups, including changes in height after 6 and 12 months, were compared. In addition, changes in height between the two groups after 6 and 12 months were compared. Data gathered from each group at the start of GH therapy were compared. Small for gestational age (SGA) is defined as a birth weight of 2 years or <2 years of BA delay. Delayed BA (>2 years) may impact the response to GH treatment in SGA children with short stature. When height SDS was compared between with and without GHD, there were no significant differences. There were no significant differences between the two groups in terms of gestational age and weight at birth, height SDS, IGF-1 SDS, and growth hormone dosage at the beginning of therapy. Of the 27 patients, 9 had 2 years of delay. We studied 27 SGA children with short stature in the pediatric endocrinology clinic of Kyungpook National University Children’s Hospital. We retrospectively analyzed changes in height SD score (SDS) and BA/chronological age (CA) after 6 and 12 months of GH therapy in patients grouped according to BA delay. To investigate the effects of GH therapy in SGA patients with short stature according to BA delay. Although GH therapy in these patients has been extensively studied, the impact of therapy according to delays in bone age (BA) is not known well. Growth hormone (GH) treatment is recommended to improve growth and psychosocial problems in short stature children born small for gestational age (SGA). ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |